drugset
drugset / Trial / NCT04398290

iNOPulse for COVID-19

NCT04398290 ↗

Phase 2 Withdrawn Roger Alvarez Bellerophon Therapeutics · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This randomized, controlled trial will assess the efficacy and safety of pulsed iNO in subjects with COVID-19 who are hospitalized and require supplemental oxygen.

Timeline

Start
2020-12-01
Primary completion
2021-06-01
Completion
2021-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitric Oxide Other / unclassified 250 ug/kg Inhaled
Background Oxygen Other / unclassified — Inhaled

Indications

COVID-19 respiratory failure